212 related articles for article (PubMed ID: 22707405)
1. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
4. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
5. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
9. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
[TBL] [Abstract][Full Text] [Related]
10. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
[TBL] [Abstract][Full Text] [Related]
12. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
13. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
15. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
[TBL] [Abstract][Full Text] [Related]
16. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
[TBL] [Abstract][Full Text] [Related]
17. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
18. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
Dispenzieri A; Seenithamby K; Lacy MQ; Kumar SK; Buadi FK; Hayman SR; Dingli D; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Johnston PB; Porrata LF; Patnaik MM; Hogan WJ; Gertz MA
Bone Marrow Transplant; 2013 Oct; 48(10):1302-7. PubMed ID: 23604010
[TBL] [Abstract][Full Text] [Related]
19. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
20. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.
Akpek G; Lenz G; Lee SM; Sanchorawala V; Wright DG; Colarusso T; Waraska K; Lerner A; Vosburgh E; Skinner M; Comenzo RL
Bone Marrow Transplant; 2001 Dec; 28(12):1105-9. PubMed ID: 11803350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
